[1] Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res,2009,15:1411-1416.
[2] Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Expert Rev Anticancer Ther,2014,14:751-760.
[3] Massey PR, Okman JS, Wilkerson J. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer,2015,23:1827-1835.
[4] Fishman MN, Tomshine J, Fulp WJ, et al. A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting. PloS one,2015,10:e0120877.
[5] Degen A, Alter M, Schenck F, et al. The hand‐foot‐syndrome associated with medical tumor therapy-classification and management. J Dtsch Dermatol Ges,2010,8: 652-661.
[6] Lee SH, Song IH, Noh R, et al. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retro-spective study of routine clinical practice in multi-institutions. J Gastroenterol Hepatol,2015,15:1463-1469.
[7] Cho JY, Paik YH, Lim HY, et al. Clinical parameters predictive of outcomes in sorafenib‐treated patients with advanced hepatocellular carcinoma. Liver Int,2013,33 :950-957.
[8] Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predictbetter outcome in HCC patients treated with sorafenib. J Hepatol, 2014,61:318 -324.
[9] Di Costanzo GG, de Stefano G, Tortora R, et al. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncol,2015,11:943-951.
[10] Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol,2013,13:176-181.
[11] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials,2007,8:16
[12] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol,2010, 25:603-605.
[13] Nault JC, Pigneur F, Nelson AC, et al. Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. Dig Liver Dis,2015,47:869- 876.
[14] Yada M, Masumoto A, Motomura K, et al. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol,2014,20: 12581-12587.
[15] Otsuka T, Eguchi Y, Kawazoe S, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res,2012,42:879-886.
[16] Yao X, Yan D, Liu D, et al. Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. Mol Clin Oncol,2015,3:929-935.
[17] Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a pre-dictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist,2010, 15:85-92.
[18] Shomura M, Kagawa T, Shiraishi K, et al. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular car-cinoma. World J Hepatol, 2014,6 :670-676.
[19] Ogasawara S, Chiba T, Ooka Y, et al. Sorafenib treatment in Child- Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs,2015,33:729-739.
[20] Koschny R, Gotthardt D, Koehler C, et al. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology,2013, 84:6-13.
[21] Cheng WC, Chung IF, Chen CY, et al. DriverDB: an exome sequencing database for cancer driver gene identification. Nucleic Acids Res, 2014, 42(Database issue): D1048-1054.
[22] Shiba S, Okusaka T, Ikeda M, et al. Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatol Res, 2014,44,1268-1276. |
